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This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e17. Learning
Objective: Upon completion of this CME activity, successful learners will be able to recognize current screening and treatment
guidelines for hepatocellular carcinoma (HCC), describe gaps in existing evidence supporting HCC screening, and explain how
unique research methodologies, including the case-control study design, addresses these voids.BACKGROUND & AIMS: Screening patients with cirrhosis for
hepatocellular carcinoma (HCC) has been recommended. We
conducted a matched case–control study within the US Veter-
ans Affairs (VA) health care system to determine whether
screening by abdominal ultrasonography (USS) and/or by
measuring serum level of a-fetoprotein (AFP) was associated
with decreased cancer-related mortality in patients with
cirrhosis. METHODS: We defined cases (n ¼ 238) as patients
with cirrhosis who died of HCC from January 1, 2013 through
August 31, 2015 and had been in VA care with a diagnosis of
cirrhosis for at least 4 years before the diagnosis of HCC. We
matched each case to 1 control (n ¼ 238), defined as a patient
with cirrhosis who did not die of HCC and had been in VA care
for at least 4 years before the date of the matched case’s HCC
diagnosis. Controls were matched to cases by year of cirrhosis
diagnosis, race and ethnicity, age, sex, etiology of cirrhosis,
Model for End-Stage Liver Disease score, and VA medicalcenter. We identified all USS and serum AFP tests performed
within 4 years before the date of HCC diagnosis in cases or the
equivalent index date in controls and determined by chart
extraction (blinded to case or control status) whether these
tests were performed for screening. RESULTS: There were no
significant differences between cases and controls in the pro-
portions of patients who underwent screening USS (52.9% vs
54.2%), screening measurement of serum AFP (74.8% vs
73.5%), screening USS or measurement of serum AFP (81.1%
vs 79.4%), or screening USS and measurement of serum AFP
(46.6% vs 48.3%) within 4 years before the index date, with or
without adjusting for potential confounders. There also was no
difference in receipt of these screening tests within 1, 2, or 3
years before the index date. CONCLUSIONS: In a matched case–
control study of the VA health care system, we found that
screening patients with cirrhosis for HCC by USS, measurement
of serum AFP, either test, or both tests was not associated with
decreased HCC-related mortality. We encourage additional
case–control studies to evaluate the efficacy of screening for
HCC in other health care systems, in which available records
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
The matched case-control study design is the best
observational study design for determining whether
screening reduces cancer-related mortality. A case-
control study of HCC screening in patients with cirrhosis
has not yet been performed.atients with cirrhosis have a high risk of hepatocel-
are sufficiently detailed to enable identification of the indica-
tion for USS and AFP tests.
Keywords: Surveillance; Survival; Liver Cancer; Liver 
Transplantation.NEW FINDINGS
HCC screening with ultrasonography, AFP, or both was
not associated with decreased HCC-related mortality.
This contrasts with many “cohort studies” of HCC
screening, which are susceptible to lead-time and
length-time bias.
LIMITATIONS
The main limitation of case-control studies of screening
effectiveness is misclassification of tests performed
among cases for suspected cancer as screening tests.
IMPACT
Current strategies for HCC screening have been based on
ultrasonography ± AFP for more than 25 years. The
authors hope that this study will lead to renewed efforts
to develop and validate better screening tests.
Abbreviations used in this paper: AASLD, American Association for the
Study of Liver Diseases; AFP, a-fetoprotein; CAPRI, Compensation and
Pension Record Interchange; CI, confidence interval; CDW, Corporate
Data Warehouse (Veterans Affairs); CT, computed tomography; DPP,
detectable preclinical phase; HCC, hepatocellular carcinoma; HCV, hep-
atitis C virus; ICD-9, International Statistical Classification of Diseases,
Injuries and Causes of Death, Ninth Edition; MELD, Model for End-Stage
Liver Disease; MRI, magnetic resonance imaging; OR, odds ratio; RCT,
randomized controlled trial; USS, ultrasound scan; VA, Veterans Affairs.Plular carcinoma (HCC), ranging from 1% to 8% per
year.1 Most professional liver societies recommend
screening patients with cirrhosis with abdominal ultraso-
nography (USS) with or without concomitant serum
a-fetoprotein (AFP) testing every 6 months,2–4 but many
non-liver societies do not endorse HCC screening.5,6 The
rationale for HCC screening in patients with cirrhosis is that
screening tests such as USS or serum AFP could identify
patients with HCC at an early stage when they have
potentially curative or life-prolonging treatment options,
including liver transplantation, radiofrequency ablation, or
surgical resection. However, it remains unclear whether
HCC screening decreases cancer-related mortality in
patients with cirrhosis, which should be the primary end
point of HCC screening, rather than early-stage migration or
increased frequency of receipt of potentially curative
treatments.
Two randomized controlled trials (RCTs) of HCC
screening have been performed.7,8 However, these trials
reached conflicting conclusions about screening effective-
ness, and their methodology has been criticized.9 Also, their
results do not necessarily apply to North American and
European patients with cirrhosis in the current era, because
the trials were conducted in China from 1989 to 1997 in
patients with chronic hepatitis B virus infection. HCC related
to hepatitis B virus can occur in the absence of cirrhosis and
important advances in the treatment of HCC have occurred
since these studies were conducted.
Many observational studies have compared survival in
patients diagnosed with HCC by screening with those who
presented with symptomatic HCC. These studies were
summarized in 2 systematic reviews,9,10 which concluded
that the interpretation of these observational studies was
limited because of selection, verification, and lead-time and
length-time biases.
Ideally, the effectiveness of HCC screening would be
evaluated by a study that randomizes patients with cirrhosis
to screening vs no screening. However, as concluded by the
authors of the American Association for the Study of Liver
Diseases (AASLD) HCC guidelines11 and demonstrated by
problems in patient recruitment encountered in a pilot
study,12 it is unlikely that such randomized trials of HCC
screening will be feasible in the United States, where HCC
screening has become the de facto standard of care. None-
theless, concerns have been raised that HCC surveillance has
been adopted in the United States without sufficient data to
demonstrate its efficacy.13,14
As an alternative to RCTs, case–control studies have the
potential to evaluate the effectiveness of cancer screening in
an efficient manner.15–17 To test for an effect of screening on
cancer-related mortality, previous receipt of the screeningtest (eg, abdominal USS or serum AFP testing) was
compared in patients with cirrhosis who died of HCC (cases)
and in a matched sample of patients with cirrhosis who did
not die of HCC (controls). A lower likelihood of screening
before diagnosis during the time when the malignancy is
occult but potentially detectable by the screening modality
in those who die of cancer would provide evidence in sup-
port of a protective effect of screening on mortality. Thus, if
HCC screening were effective, then we would expect
patients who died of HCC to be less likely to have been
screened than patients with cirrhosis who did not die of
HCC. By selecting patients with fatal, rather than incident,
cancers as case subjects, this case–control paradigm ad-
dresses the impact of screening on cancer-related mortality
and is not susceptible to length-time or lead-time bias. The
odds ratio (OR) in a bias-free case–control study of
screening would be a valid estimate of the risk ratio that
might be obtained from an RCT.15
The case–control study design has been used previously
to evaluate screening effectiveness for malignancies other
than HCC, such as colorectal cancer,18,19 breast cancer,20
esophageal cancer,21 cervical cancer,22 prostate cancer,23
Figure 1. Schematic representation of the case–control study design, illustrating the criteria used to match cases (fatal HCC)
to controls, the index date, and the DPP. The DPP consisted of an identical period of calendar years for the case and control
within each matched pair (eg, 2010–2014 in the example), during which the case and control were in VA care at the same VA
facility. *Index date is the date of HCC diagnosis or the earliest date that patients showed symptoms, laboratory abnormalities,
or imaging findings suspicious for HCC. †The DPP is the period before the index date during which we documented the
occurrence of screening USS or serum AFP. ‡Cases and controls were matched by age, sex, race, etiology of cirrhosis, MELD
score at the time of cirrhosis diagnosis, date of cirrhosis diagnosis, and VA facility.and melanoma.24 We performed a matched case–control
study to evaluate the extent to which screening for
HCC with USS or serum AFP would be associated with
decreased HCC-related mortality in patients with cirrhosis
in the US Veterans Affairs (VA) health care system, the
largest integrated health care system in the United States.Methods
Overall Study Design: Matched Case–Control
Study of Screening Effectiveness
We defined cases as VA patients with cirrhosis who died of
HCC from January 1, 2013 through August 31, 2015 and had at
least 4 years of follow-up time enrolled in the VA from the date
of cirrhosis diagnosis to the date of HCC diagnosis. We matched
each case to 1 control, defined as a VA patient with cirrhosis
who did not die of HCC, was not diagnosed with HCC as of the
date of the matched case’s HCC diagnosis, and was in VA care at
least 4 years before the date of the matched case’s HCC diag-
nosis (Figure 1). Cases were compared with controls for
abdominal USS or serum AFP tests performed for HCC
screening during the 4 years before the diagnosis of HCC in
cases or the equivalent index date in matched controls. A
smaller proportion of cases than controls receiving HCC
surveillance would suggest an association between HCC sur-
veillance and decreased HCC-related mortality.
Data Sources: National VA Corporate Data
Warehouse and Medical Chart Extraction
The VA uses a single, nationwide, comprehensive electronic
health care information network. Data from this network reside
on the Corporate Data Warehouse (CDW), a national, continu-
ally updated data repository developed specifically to facilitate
research.25 We extracted data on all pharmacy prescriptions,
demographics, inpatient and outpatient visits, problem lists,procedures, vital signs, diagnostic tests, and laboratory tests for
patients with a diagnosis of cirrhosis who were in VA care
during or before 2015. These CDW data were used only to
identify potential cases and controls for this study. Once
potential cases and controls were identified from the CDW,
their electronic medical records were accessed using the
Compensation and Pension Record Interchange (CAPRI), an
electronic interface providing online access to veterans’ medi-
cal records at all VA facilities in the country. The CAPRI was
used to obtain radiology reports, pathology reports, and inpa-
tient and outpatient progress notes. These detailed records
were electronically copied onto a specifically designed
REDCap26 database. The extracted records were reviewed by a
physician-investigator blinded as case–control status.Identification of Cases: Patients With Fatal HCC
Identification and confirmation of cases was a 2-step
process (Figure 2). First, potential cases were identified elec-
tronically from the CDW as patients with a diagnosis of
cirrhosis based on appropriate International Classification of
Diseases, Ninth Edition (ICD-9) codes (Supplemental Table 1)
recorded at least twice27–33 who were diagnosed with HCC at
least 4 years after the diagnosis of cirrhosis, died from January
1, 2013 through August 31, 2015, and had a Model for End-
Stage Liver Disease (MELD) score lower than 20 at all times
before the HCC diagnosis. We used the presence of ICD-9 code
155.0 (primary liver cancer) recorded at least twice for this
preliminary identification of HCC, as in previous studies.29,30,33–37
A 4-year period was chosen to allow enough time for screening
to plausibly have an influence on HCC-related mortality. The
interval 2013–2015 was selected because it was the most
recent at the time the study was initiated, such that the most
“current” treatments would be available to patients diagnosed
with HCC. Patients with a MELD score of at least 20 were
excluded because screening is not recommended in patients
with advanced liver dysfunction (unless they are listed for
Figure 2. Flowchart demonstrating the identification and confirmation of cases, identification and confirmation of controls and
matching to cases, and identification of USS and serum AFP tests performed before the index date.
liver transplantation). Including such patients might have 
biased the results in the direction of not finding an association 
between screening and decreased cancer-related mortality. 
Second, the medical records of potential cases were accessed 
at all VA facilities nationally through the CAPRI by a physician-
investigator blinded to screening status to confirm the diag-
nosis of cirrhosis and HCC, identify the patients in whom HCC 
contributed to the patients’ death, and determine the index 
date. The diagnosis of cirrhosis was based on clinical features 
of portal hypertension from liver disease (ascites, hepatic 
encephalopathy, varices), characteristic laboratory features 
(eg, decreased platelets, prolonged prothrombin time, 
increased serum bilirubin, hypoalbuminemia), imaging 
characteristics (eg, nodular liver, portosystemic collaterals), 
liver biopsy results, and/or diagnosis documented by a 
gastroenterologist or hepatologist. The diagnosis of HCC was 
defined by the following national AASLD criteria that were in 
effect at the time our study was conducted11,38: (1) liver 
nodules at least 10 mm that were hypervascular in the arterial 
phase with washout in the portal venous or delayed phase at 
4-phase multidetector computerized tomography (CT) or dy-
namic contrast-enhanced magnetic resonance imaging (MRI);
(2) liver nodules that fulfilled the 5 criteria of the Liver 
Imaging Reporting and Data System; or (3) liver lesions with 
histology consistent with HCC at biopsy examination.
For patients confirmed to have HCC, the physician-
investigator determined whether HCC definitely contributed 
to the patient’s death, which was defined as presence of met-
astatic HCC, multifocal HCC (>3 lesions), local or vascular in-
vasion by HCC, large-volume HCC (>6 cm), serum AFP level 
higher than 1,000 ng/mL, or death from complications from 
HCC treatment in patients who did not have an obvious alter-
native cause of mortality. Only patients confirmed to have HCC 
in whom HCC “definitely” contributed to death were included 
as cases in the study.
The diagnostic definition of HCC and the criteria used to 
define that HCC contributed to the patient’s death were 
determined and validated before study initiation by a pilot 
study of a different set of 50 cases of fatal HCC reviewed 
independently by 2 of the investigators. There was excellent 
inter-rater agreement (97.5% agreement, k ¼ 0.94, P < .001) 
between the 2 investigators in assigning whether HCC defi-
nitely contributed to the patient’s death using the criteria 
described earlier.
Identification of Matched Controls
Identification and confirmation of matched controls was a 
2-step process (Figure 2). First, we electronically identified 
from the CDW all patients with a diagnosis of cirrhosis,27–33 
defined using the same ICD-9 codes as for cases, who did not 
die of HCC and were not diagnosed with HCC before their 
matched case’s index date. We matched 1 control to each case 
by the following characteristics, which are strongly associated 
with fatal HCC and the likelihood of screening: (1) year of 
cirrhosis diagnosis; (2) race and ethnicity (categorized as white 
non-Hispanic, black non-Hispanic, Hispanic, other); (3) age 
(within 2 years); (4) sex; (5) primary etiology of cirrhosis 
(hepatitis C virus [HCV], alcoholic liver disease, nonalcoholic 
fatty liver disease, or other as previously published39; see 
Supplemental Table 2 for definitions); (6) MELD score at time 
of cirrhosis diagnosis (within 2 points); and (7) VA facility inwhich the diagnosis of cirrhosis was made. Controls had to be
enrolled in VA care for the 4 years before the index date and
alive at the time of their matched case’s death. Controls who
had a MELD score of at least 20 at any time before the index
date of their matched case were excluded (as were cases).
Second, the medical records of potential controls were accessed
at all VA facilities nationally through the CAPRI by a physician-
investigator who was blinded to screening status to confirm the
diagnosis and etiology of cirrhosis.Definition of Index Date
The index date for cases was defined as the date of HCC
diagnosis (ie, the earliest date of a multiphasic CT or MRI or
tissue biopsy finding diagnostic for HCC) or the earliest date
that patients reported symptoms (eg, weight loss, abdominal
pain), imaging findings (eg, suspicious liver nodule at screening
USS), or laboratory abnormalities suspicious for HCC (eg,
increased serum AFP), whichever came first. The index date
was determined for each case by review of the medical records
by a physician-investigator. By definition, an USS or serum AFP
test performed after the index date could not have been a
screening test. For example, if a screening USS showed a sus-
picious liver nodule and a serum AFP was subsequently
ordered, the index date was the date of the USS and the serum
AFP was not considered a screening test. Each control was
assigned the same index date as the matched case. Therefore,
for each case–control pair, we evaluated an identical calendar
period before the index date for presence of screening USS or
AFP (Figure 1). Cases or controls with index dates occurring
less than 4 years after the diagnosis of cirrhosis were excluded,
because this would not have allowed us to examine screening
histories for the full duration of a maximum hypothesized
4-year detectable preclinical phase of HCC.
Determination of Screening USS and Serum AFP
in Cases and Controls
Each abdominal USS test performed within 4 years before
the index date was identified electronically by an analyst
blinded to case–control status. The USS report (which included
the recorded indication for performing the USS) and the
ordering provider’s progress notes before and after the USS
were electronically copied from the medical records onto a
REDCap database by a trained research assistant as a separate
record for each USS. A physician-investigator blinded to case–
control status reviewed this information on REDCap and cate-
gorized each USS as having been performed “definitely” for
screening, “probably” for screening, “probably not” for
screening, or “definitely not” for screening. The definitions of
these categories are presented in Supplemental Table 3.
This process was performed separately for each serum AFP
test obtained within 4 years before the index date. The progress
notes of the ordering provider before and after the AFP result
were copied from the electronic medical records and a blinded
physician-investigator categorized each AFP as having been
performed “definitely,” “probably,” “probably not,” or “defi-
nitely not” for screening using the criteria listed in
Supplemental Table 4.
The principal investigator also reviewed any records that
were difficult to categorize by the physician-investigator and a
random 10% sample of all records.
The criteria for adjudicating the screening status of USS and 
serum AFPs were determined by an independent chart 
extraction by 2 investigators of a different set of 50 cases and 
50 controls before the study was initiated. There was excellent 
agreement between the 2 investigators for the criteria used in 
the study (94.2% agreement, k ¼ 0.90, P < .001).
The primary analysis considered only USS or serum AFP 
tests performed “definitely” for screening, but a sensitivity 
analysis also included those performed “probably” for screening.
Statistical Analysis
Cases were compared with their matched controls for 
receipt of abdominal USS or serum AFP performed for 
screening within 0–1, 0–2, 0–3, or 0–4 years before the index 
date modeled as binary (yes or no) variables using conditional 
logistic regression. This period, the detectable preclinical phase 
(DPP), is the period from the earliest time at which the cancer is 
potentially detectable using the screening modality under study 
to the time at which the cancer would present clinically in the 
absence of screening. Sheu et al40 estimated the DPP for HCC by 
estimating the time it would take for HCCs to grow from 1 cm 
(minimum size potentially detectable by USS) to 10 cm (a size 
generally expected to cause symptoms) as 3.2 years for tumors 
with a median growth rate, which had a doubling time of 117 
days. Based on this, we chose 4 years as the upper limit of the 
DPP, that is, we estimated that a small HCC that could be 
detectable by USS would take a maximum of 4 years before 
presenting with clinical symptoms.40 The maximal DPP is 
believed to provide the least biased estimate of any true as-
sociation between receipt of screening and decreased cancer-
related mortality.41 However, it also has been shown that 
when different periods are analyzed yielding different ORs, the 
lowest OR (ie, the one that indicates the greatest survival 
benefit for screening) is likely to be the least biased.41 For these 
reasons, we analyzed screening tests performed within 4 years 
before the index date (ie, close to the estimated maximal DPP) 
as our primary analysis, but also analyzed screening tests 
performed within 1, 2, or 3 years before the index date. We did 
not analyze tests performed 6 months before the index date, 
because this short interval would be heavily biased toward 
showing a higher rate of screening for cases than for controls 
(ie, erroneously making it appear as if screened patients are 
more likely to die of HCC).
Cases and controls were not compared for the number of 
screening tests during the DPP, because even in the absence of 
effective therapy of screen-detected cancers, the cases would be 
expected to have been screened fewer times than the controls, 
assuming that the screening test is sensitive in identifying the 
tumor, producing a spuriously low OR associated with multiple 
(or “regular”) screening.16,17 If a case with occult liver cancer 
undergoes a screening test, then the cancer might be identified 
and a second (or third) test will never take place. However, 
controls (the large majority of whom do not have liver cancer) 
have the capacity to be screened more than once during the 
interval under consideration.
Conditional logistic regression models were adjusted for 
age, etiology of cirrhosis (HCV, nonalcoholic fatty liver disease, 
alcoholic liver disease, and other), MELD score at cirrhosis 
diagnosis, race and ethnicity, year of cirrhosis diagnosis, dia-
betes, alcohol use disorders, body mass index, eradication of 
HCV by antiviral treatment, and receipt of abdominal CT or MRIduring the period of interest. Models that evaluated the effec-
tiveness of screening serum AFP also were adjusted for receipt
of screening USS and models that evaluated the effectiveness of
screening USS also were adjusted for receipt of screening
serum AFP.
We evaluated the following binary screening variables in
different conditional logistic regression models:
1. Screening USS vs no screening USS
2. Screening serum AFP vs no screening AFP
3. Screening USS or serum AFP vs no screening with USS or
serum AFP
4. Screening with USS and serum AFP vs screening with
only USS
5. Screening with USS and serum AFP vs screening with
only AFP
6 Screening with USS and serum AFP vs screening with
none
Power Calculations
Extrapolating from a prior VA study,33 we estimated that the
proportion of controls with a screening serum AFP or a
screening USS during a 4-year period in our study would be
approximately 70%. Using the method of Dupont42 specifically
for power calculations in matched case–control studies, we
calculated a priori that 238 cases matched to 238 controls would
provide more than 90% power to detect a 14% difference in
screening between cases and controls and more than 80%
power to detect a 12% difference between cases and controls
(eg, 70% screening for controls and 58% screening for cases).
Results
Aiming for a sample size of 238 pairs of cases and
matched controls, we initially identified electronically a
random sample of 600 potential cases and 1,800 potential
matched controls. After reviewing the charts of 497 of these
600 potential cases in random sequence, we excluded 10
patients who did not have HCC, 49 patients in whom HCC
did not definitely contribute to patient death, 165 patients
who did not have cirrhosis or had an interval shorter than
4 years between the diagnosis of cirrhosis and the index
date, 23 patients for other reasons (care elsewhere, n ¼ 4;
insufficient documentation, n ¼ 8; unclear cause of death,
n ¼ 8; unclear HCC diagnosis, n ¼ 3), and 12 patients who
could not be matched to a control who fulfilled all matching
criteria, leaving 238 cases in the present analysis (Figure 2).
After reviewing the charts of 322 potential controls elec-
tronically matched to these cases, we excluded 84 who did
not have cirrhosis or had an interval shorter than 4 years
between the diagnosis of cirrhosis and the index date,
leaving 238 controls in the present analysis, each matched
to a single case.
Characteristics of Cases and Controls
As expected by the matching scheme, cases and controls
were the same for age at diagnosis of cirrhosis (54.6 years),
age at index date (62.5 years), racial and ethnic distribution,





Men, % 100 100
Age at diagnosis of cirrhosis (y), mean 54.5 54.6
Age at index date (y), mean 61.9 62.0
Year of cirrhosis diagnosis, %




Interval from diagnosis of
cirrhosis to index date, y
7.9 7.9






White, non-Hispanic 74 74
Black, non-Hispanic 15 15
Hispanic 10 10
Other 1.3 1.3
Primary etiology of liver disease, %
HCV 80 80
Alcoholic liver disease 13 13
Nonalcoholic fatty liver disease 2.9 2.9
Other 4.2 4.2
Sustained virologic response
to HCV achieved before index
date (in those with HCV), %
14 8.4
BMI (kg/m2), mean 29 29
MELD score, mean 9.1 9.0
Diabetes, % 23 23
Alcohol use disorders, % 48 61
CT or MRI before index date, %
0–2 y 44 55
0–3 y 53 62
0–4 y 62 71
BMI, body mass index.
Table 2.Characteristics of HCC in Cases (Fatal HCC)
Cases, n (%)
Method of HCC diagnosisa
Imaging (CT or MRI) 204 (86)
Histology 69 (29)
Stage of HCC at diagnosis
Maximum dimension of largest
tumor (cm), mean (SD)
4.5 (3.4)
Number of tumors, mean (SD) 2.1 (1.6)




Size of largest tumor (%)
0–3 cm 92 (39)
3–<5 cm 75 (32)
5–<6 cm 16 (6.7)
6–<7 cm 15 (6.3)
7 cm 40 (17)
Within Milan criteria (%)b 122 (51)
Beyond Milan criteria (%) 116 (49)
Vascular invasion, % 38 (16)
Metastasis, % 19 (8)
Treatment of HCCa
Liver transplantation 0 (0.0)
Surgery (partial hepatectomy) 5 (2.1)
Systemic chemotherapy (sorafenib) 69 (29)
Transarterial chemoembolization 101 (42)
Radiofrequency ablation 30 (13)
Y-90 radio embolization 7 (2.9)
Percutaneous ethanol injection 3 (1.3)
Cryoablation 1 (0.4)
Other treatment 11 (4.6)
Any of above treatments 159 (67)
HCC contributed to patient’s deatha
Metastatic HCC 49 (21)
Multifocal HCC (>3 lesions) 77 (32)
Local or vascular invasion by HCC 64 (27)
Large-volume HCC (>6 cm
or AFP > 1,000 ng/mL)
107 (45)
Death from complications of HCC treatment 6 (2.5)
aThe categories for “method of HCC diagnosis,” “treatment of
HCC,” and “HCC contributed to patient’s death” are not
mutually exclusive.
bMilan criteria: 1 tumor smaller than 5 cm or 2–3 tumors each
of which is smaller than 3 cm.year of cirrhosis diagnosis, year of index date, interval from
cirrhosis diagnosis to index date, MELD score at time of
cirrhosis diagnosis, and primary etiology of cirrhosis
(Table 1). All cases and controls were men, reflecting the
predominantly male VA population (by chance no women
met all the inclusion criteria for cases). In most patients, the
primary etiology of cirrhosis was HCV infection (80%) or
alcoholic liver disease (13%). Most patients were white
(73.5%) followed by black (15.1%) and Hispanic (10.1%)
race and ethnicity. Patients had a mean MELD score of 9 at
the time of cirrhosis diagnosis. HCV infection had been
cured by antiviral treatment before the index date in 13.7%
of controls and 8.4% of cases.
Characteristics of HCC in Cases
In most cases, HCC was diagnosed by appropriate
multiphasic CT or MRI (85.6%), whereas 28.8% hada histologic diagnosis (Table 2). At the time of diagnosis,
16.0% had vascular invasion, 8.0% had metastatic disease,
and 51.3% were within Milan criteria. A large proportion of
patients received locoregional treatments, including trans-
arterial chemoembolization in 42.4% and radiofrequency
ablation in 12.7%, whereas 28.4% were treated with sor-
afenib and only 2.1% underwent surgical resection. The
criteria that were used to determine that the presence of
HCC contributed to the patient’s death most commonly
included large-volume HCC (45.0%), multifocal HCC
(32.4%), local or vascular invasion (26.9%), or metastasis
(20.6%).
Table 3.Distribution of USS and Serum AFP Tests During 0–4
Years Before Index Date
Controls Cases
USS
All USS tests 503 492
Definitely screening 287 (57.1%) 284 (57.7%)
Probably screening 6 (1.1%) 8 (1.6%)
Probably not screening 4 (0.8%) 2 (0.4%)
Definitely not screening 206 (41.0%) 198 (40.2%)
AFP
All AFP tests 848 795
Definitely screening 641 (75.6%) 635 (79.9%)
Probably screening 10 (1.2%) 2 (0.3%)
Probably not screening 0 (0.0%) 0 (0.0%)
Definitely not screening 197 (23.2%) 158 (19.9%)Association Between Screening and
HCC-Related Mortality
During the 4-year period before the index date, cases
underwent 492 USS and 795 serum AFP tests (including
284 and 635, respectively, performed “definitely for
screening”) and controls underwent a similar number of
503 USS and 848 serum AFP tests (including 287 and
641, respectively, performed “definitely for screening”;
Table 3).
There was no difference between cases and controls in
the proportion who underwent screening USS (52.9% vs
54.2%, OR 0.95, 95% confidence interval 0.66–1.37),
screening serum AFP (74.8% vs 73.5%, OR 1.07, 95% CI
0.70–1.65), or screening USS or AFP (81.1% vs 79.4%, OR
1.12, 95% CI 0.70–1.81) within 4 years before the index
date (Table 4). There also was no difference in receipt of
these screening tests within 1, 2, or 3 years before the index
date. After adjustment for potential confounders, there was
no association between screening with USS or AFP and
HCC-related mortality (Table 4).
Receipt of screening with USS and AFP was not associ-
ated with HCC-related mortality compared with receipt of
USS alone, AFP alone, or no screening at any of the intervals
studied (1, 2, 3, or 4 years; Supplemental Table 5).
When we analyzed USS and serum AFP tests that were
done definitely or probably for screening (instead of
only tests done definitely for screening), we found no
association between screening and HCC-related mortality
(Supplemental Tables 6 and 7).Discussion
HCC screening with USS and/or serum AFP was not
associated with decreased risk of HCC-related mortality in
this matched case–control study based on recent data from
a national health care system in the United States.
Consensus on HCC screening recommendations is lack-
ing among professional societies. Most liver societies such
as the AASLD,2 the European Association for the Study of the
Liver,3 and the Asian Pacific Association for the Study of theLiver4 have recommended USS every 6 months with or
without concomitant serum AFP for HCC surveillance in
patients with cirrhosis. In contrast, non-liver societies have
not endorsed HCC screening because of the lack of high-
quality data. The US Preventive Services Task Force has
not adopted an HCC practice guideline, the American Cancer
Society makes no recommendation on HCC screening,5 and
the National Cancer Institute found no evidence that
screening decreases mortality from HCC but did find
evidence that screening could result in harm.6
It remains unclear whether HCC screening decreases
HCC-related mortality. Although 2 RCTs were performed in
patients with hepatitis B virus infection in China before
1997, their results do not apply to patients with cirrhosis in
the current era in the United States and have been criticized
for methodologic limitations.9 The remaining studies
were observational, including 39 aggregated in 2 meta-
analyses9,10 and 1 large VA study published subse-
quently.43 However, these studies did not compare
HCC-related mortality in screened vs unscreened patients.
Rather, they compared survival after the diagnosis of HCC in
patients whose HCC was diagnosed because of screening vs
those in whom HCC presented with symptoms. This study
design is inherently susceptible to lead-time bias that can
lead to overestimation of the benefits of screening. Several
studies have attempted to adjust for lead-time bias by
estimating the “sojourn time”44 (the period during which
the tumor is asymptomatic but detectable by screening)
using estimates of tumor growth rate or doubling time. The
conclusions of these studies vary dramatically depending on
the estimates of tumor doubling time and sojourn time used
to adjust for lead-time bias.45,46 In addition, this study
design is limited by length-time bias (aggressive tumors are
more likely to present symptomatically and less likely to be
diagnosed by screening than less aggressive tumors) and by
selection bias (patients who underwent screening were a
selected subset of all patients with cirrhosis who might have
had improved survival by having access to better overall
care). Moreover, most of these studies did not adjust for
MELD score, a critical determinant of survival in patients
with HCC.
Our methodology addresses many of the limitations of
prior studies examining HCC screening. We used a matched
case–control study design to evaluate HCC screening effec-
tiveness that is not susceptible to lead-time or length-time
bias. Because cases are defined as patients with cirrhosis
and fatal HCC, this study design yields estimates of the
impact of screening on HCC-related mortality and approxi-
mates the results that would be expected from a random-
ized controlled trial.15 We evaluated a large number of cases
and matched controls who were derived randomly from a
national health care system that provides care to 8 million
veterans in 180 medical centers across the entire United
States; thus, our findings are typical of community-based
settings. All VA patients have uniform access to medical
care, limiting bias owing to differential access to HCC
screening and HCC treatments. Potential cases and controls
were individually verified by chart review using
Table 4.Comparison of Cases and Controls for Occurrence of Screeninga USS, Screening AFP, or USS or AFP at Given
Intervals Before Index Date
Controls
(n ¼ 238), n (%)
Cases





0–4 y before index date
USS 129 (54.2) 126 (52.9) 0.95 (0.66–1.37) 0.95 (0.63–1.43)
AFP 175 (73.5) 178 (74.8) 1.07 (0.70–1.65) 1.08 (0.67–1.75)
USS or AFP 189 (79.4) 193 (81.1) 1.12 (0.70–1.81) 1.11 (0.68–1.82)
0–3 y before index date
USS 117 (49.2) 112 (47.1) 0.92 (0.63–1.32) 0.91 (0.60–1.37)
AFP 164 (68.9) 168 (70.6) 1.09 (0.73–1.63) 1.13 (0.72–1.77)
USS or AFP 177 (74.4) 182 (76.5) 1.13 (0.73–1.74) 1.14 (0.72–1.79)
0–2 y before index date
USS 95 (39.9) 91 (38.2) 0.93 (0.63–1.36) 0.93 (0.60–1.43)
AFP 145 (60.9) 151 (63.4) 1.13 (0.76–1.69) 1.18 (0.76–1.83)
USS or AFP 160 (67.2) 165 (69.3) 1.12 (0.74–1.68) 1.12 (0.73–1.73)
0–1 y before index date
USS 62 (26.1) 70 (29.4) 1.20 (0.79–1.81) 1.20 (0.77–1.86)
AFP 109 (45.8) 121 (50.8) 1.24 (0.85–1.80) 1.22 (0.82–1.82)
USS or AFP 127 (53.4) 143 (60.1) 1.33 (0.92–1.94) 1.40 (0.95–2.08)
aOnly tests performed “definitely for screening” were included in this analysis.
bOR of screening in cases relative to controls. An OR less than 1 would be indicative of an association between HCC sur-
veillance and decreased HCC-related mortality. Although this OR is unadjusted, cases and controls were matched for age,
sex, race, etiology of cirrhosis, MELD score at time of cirrhosis diagnosis, date of cirrhosis diagnosis, and VA facility.
cAdjusted for age, etiology of cirrhosis, MELD score at cirrhosis diagnosis, race and ethnicity, year of cirrhosis diagnosis,
diabetes, alcohol use disorders, body mass index, eradication of HCV by antiviral treatment, and receipt of abdominal CT or
MRI during the period of interest. Also, USS analysis was adjusted for screening for serum AFP and serum AFP analysis was
adjusted for screening by USS.prespecified criteria. Cases were limited to patients who
died within a very recent period (2013–2015), such that
current treatments for HCC would be available to poten-
tially affect HCC-related mortality. Controls were matched
to cases for important characteristics that affect receipt of
screening or death from HCC, and additional potential
confounders were adjusted for. Blinding to the case or
control status of patients was maintained for the analyst
who identified all USS and serum AFP tests performed in
the 4 years before the index date, the research assistant
who copied relevant reports from the electronic medical
records onto our REDCap database, and the physician-
investigator who determined whether USS or serum AFP
tests were done for screening. The medical records related
to each of the 995 USS and 1643 AFP tests performed in
the 4-year period before the index date were reviewed by
a physician-investigator to determine whether the USS or
AFP test was performed for screening. We excluded cases
and controls who had a MELD score of at least 20 before
the index date, because screening is not recommended in
patients with decompensated cirrhosis (unless they are
listed for liver transplantation) because they are unlikely
to benefit from HCC treatment.
Our study had several potential limitations. It was
conducted in a male population of US veterans, which might
limit the generalizability of our study to women. However,
we are not aware of studies showing that the test charac-
teristics of screening USS or serum AFP or the outcomes of
HCC treatment are different in men vs women withcirrhosis. Nonetheless, it would be useful to replicate our
case–control study in a different health care system whose
records would allow the accurate identification of the indi-
cation for USS and AFP testing because, to our knowledge,
this is the only available case–control study of HCC
screening effectiveness. The main limitation of case–control
studies of cancer screening effectiveness is the potential for
misclassifying as screening tests some tests that were
actually done to evaluate symptoms or signs of cancer in the
cases. In our study, some USS or serum AFP tests might have
been performed in cases to evaluate suspected HCC, with
the basis for the suspicion not specifically mentioned in the
medical record. We would have misclassified these as
“screening” tests, leading to falsely high ORs and thus a
falsely low estimate of screening effectiveness. This is less
a concern for USS, for which the indication has to be
recorded in the report (which was available to us), but
potentially more of a concern for serum AFP tests, for which
the ordering provider’s progress notes were the main
source of information on test indication.
Two conditions are necessary for HCC screening to
result in a decrease in HCC-related mortality. First,
screening USS or serum AFP must be able to detect HCC at
an earlier stage than it would otherwise present as a result
of symptoms, signs, or incidental imaging. Second, treatment
must be available for this early-stage disease that yields
superior outcomes relative to treatment of disease detected
in the absence of screening. The lack of effectiveness of HCC
screening in our study could be related to failure in one or
both of these conditions. Multiple studies suggest that HCCs 
detected by screening USS or serum AFP have, on average, an 
earlier stage at diagnosis than HCCs detected by symp-toms, 
signs, or incidental imaging.33,46–49 However, this does not 
prove that screening leads to earlier detection. Another 
explanation is that screening is more likely to identify slow-
growing tumors, which have a lower stage, and more likely 
to miss the fast-growing tumors, which are identified at a 
higher stage by symptoms. It is possible that the HCCs most 
likely to lead to death are the HCCs least likely to be iden-
tified by current screening modalities at an early stage. 
Whether early treatment for HCC in patients with cirrhosis 
leads to a decrease in case fatality is questionable. Patients 
who receive locoregional treatments or surgical resection 
remain at risk of developing recurrent HCC, new HCC, and 
progressive liver dysfunction from their underlying 
cirrhosis. Liver transplantation is the only treatment that can 
cure the cancer and the underlying cirrhosis and should 
confer a survival benefit. However, only a small minority of 
patients with HCC undergo liver transplantation. In 2012, 
24,696 incident cases of HCC were reported in the US Cancer 
Statistics registry50 (which, if anything, un-derestimates the 
total number of HCC cases), whereas only 1,733 (7%) liver 
transplantations were performed for HCC in the United 
States.51 Pragmatic RCTs currently under way, which 
randomize patients to HCC surveillance outreach with 
patient education and patient navigation services vs 
“opportunistic” surveillance,52 could address the impact of 
surveillance of early detection and receipt of treatment but 
are not designed to study cancer-related mortality.
It is unlikely that the lack of screening-related survival 
benefit in our study was due to untimely diagnostic and 
confirmatory tests for HCC or unavailability of HCC treat-
ments in the VA system. First, even among these fatal cases, 
51.3% were diagnosed within Milan criteria, a much larger 
proportion than that of unselected patients with HCC in the 
national SEER registry diagnosed within Milan criteria 
(36.4% in 2003–2006 and 46.3% in 2013–2014).53 Second, 
we found that even among these fatal cases, who had very 
advanced HCC at presentation, a substantial proportion 
(66.8%) received a cancer-specific treatment. The fact that 
none of the cases received liver transplantation is not 
indicative of unavailability of liver transplantation, but 
rather a result of the fact that only carefully selected patients 
who are not expected to die of HCC undergo liver 
transplantation and, hence, liver transplant recipients did 
not contribute to the fatal cases in our study. It is unlikely 
that the lack of screening-related survival benefit was due to 
patients having advanced cirrhosis, which could discourage 
screening, preclude certain HCC treatments, or dictate 
patient survival irrespective of the presence of HCC, because 
patients had a MELD score lower than 20 at all times before 
the index date and a mean MELD score of 9 at the time of 
cirrhosis diagnosis.
In summary, we found no evidence that screening with 
USS or serum AFP decreases HCC-related mortality in pa-
tients with cirrhosis. This suggests that these screening tests 
and/or the currently available treatments are suboptimal 
and need to be improved.Supplementary Material
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Supplemental Table 1.Definition of Patient Characteristics Based on Diagnostic ICD-9 Codes Recorded at Least Twice in
Inpatient or Outpatient Records
Characteristic Code Definition
Cirrhosis 571.2 Alcoholic cirrhosis of liver
571.5 Cirrhosis of liver without mention of alcohol
456.0 Esophageal varices with bleeding
456.1 Esophageal varices without mention of bleeding
456.20 Esophageal varices in diseases classified elsewhere, with bleeding
456.21 Esophageal varices in diseases classified elsewhere, without mention of bleeding
789.5 Ascites
567.23 Spontaneous bacterial peritonitis
572.2 Hepatic coma or hepatic encephalopathy
070.44 Chronic hepatitis C with coma
572.4 Hepatorenal syndrome
Decompensated cirrhosis 456.0 Esophageal varices with bleeding
456.1 Esophageal varices without mention of bleeding
456.20 Esophageal varices in diseases classified elsewhere, with bleeding
456.21 Esophageal varices in diseases classified elsewhere, without mention of bleeding
789.5 Ascites
567.23 Spontaneous bacterial peritonitis
572.2 Hepatic coma or hepatic encephalopathy
070.44 Chronic hepatitis C with coma
572.4 Hepatorenal syndrome
Compensated cirrhosis 571.2 Alcoholic cirrhosis of liver
571.5 Cirrhosis of liver without mention of alcohol
Hepatocellular carcinoma 155.0 Hepatocellular carcinoma
Diabetes mellitus type 2 250.00–250.92 Diabetes
Alcohol use disorders 305.0–305.03 Alcohol abuse disorders
303.9–303.93 Alcohol dependence
291.81 Alcohol withdrawal
291.0 Alcohol withdrawal delirium
291.8 Other specified alcohol-induced mental disorders
291.9 Unspecified alcohol-induced mental disorders
303.00 Acute alcohol intoxication
577 Pancreatitis 2/2 EtOH
357 Alcoholic polyneuropathy
425.5 Cardiomyopathy 2/2 alcohol
980.9 Toxic effect of alcohol
305.00 Nondependent alcohol abuse
571.0x Alcoholic fatty liver
571.1x Acute alcoholic hepatitis
571.3x Alcoholic liver damage, unspecified
571.2 Alcoholic cirrhosis of liver
Hemochromatosis 275.0 Hemochromatosis (MUST exclude 275.1, 275.2, etc)
Primary biliary cirrhosis 571.6 Primary biliary cirrhosis
Autoimmune hepatitis 571.32 Autoimmune hepatitis
Primary sclerosing cholangitis 576.1 Cholangitis
Supplemental Table 2.Definitions of Categories for Etiology of Cirrhosis34
Etiology of cirrhosisa Definition
Hepatitis C virus (HCV) Patients with a positive serum HCV RNA were categorized as having HCV regardless of any additional
etiologies.
Alcoholic liver disease (ALD) Patients with ICD-9 codes for alcohol use disorders in the absence of serologic markers of chronic HCV or
hepatitis B virus infection and in the absence of ICD-9 codes for hemochromatosis, primary biliary
cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis.
Nonalcoholic fatty liver
disease (NAFLD)
Patients with diabetes (ICD-9 codes 250–250.92, recorded at least twice) or body mass index  30 kg/m2
before diagnosis of cirrhosis who did not have HCV, HBV, ALD (defined as above) or ICD-9 codes for
hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis.
NAFLD-related cirrhosis does not have pathognomonic serologic, radiologic, or histologic features—even
hepatic steatosis is frequently absent after cirrhosis develops. Hence, we adapted a clinical definition of
NAFLD based on previous work that reflects the diagnostic process used in clinical practice, in which
NAFLD is suspected in the presence of risk factors such as obesity and diabetes after exclusion of other
etiologies.
Other All other patients not meeting criteria above for HCV, ALD, or NAFLD.
aThese definitions were necessarily designed to be mutually exclusive.
Supplemental Table 3.Determination of Whether Abdominal USS Was Done for Screening or Non-Screening Indications
Assignment of indication
Indication reported in ultrasound report or in the ordering provider progress notes before and after
the USS was ordered and performed.
a. Definitely screeninga HCC (or hepatoma or liver cancer) screening or surveillance in patients with no new symptoms, signs, or test
results suggestive of HCC.
Indications completely unrelated to liver disease such as abdominal aortic aneurysm screening.
Follow-up renal cysts, etc.
b. Definitely non-screening As workup of any symptoms or signs that might be suggestive of HCC including increased (or worsening) liver
function test results; new ascites; weight loss; abdominal pain; abdominal tenderness; abdominal mass;
abdominal distention; abdominal bloating; enlarged liver; palpable liver; failure to thrive; jaundice;
increased bilirubin; variceal bleeding; or fever.
As a follow-up of another positive test result suggestive of HCC: abnormal AFP; liver abnormality on
abdominal ultrasound; liver abnormality on abdominal CT or MRI scan.
Any test done in the emergency room or as an inpatient.
c. Probably screening Screen for HCC and patient also has ascites or encephalopathy (when ascites or encephalopathy are long-
standing or unchanged).b
d. Probably non-screening Unclear if patient has symptoms or signs suspicious of HCC.
aOnly record as “definitely screening” if there is no simultaneous “non-screening” indication.
bThis refers to tests in which the provider seems to be ordering the USS with the intention of screening for HCC but also wants
a comment on the degree of ascites that is long-standing and being treated, without any obvious concern that development of
HCC might have contributed to the ascites or encephalopathy.
Supplemental Table 4.Determination of Whether a Serum AFP Test Was Done for Screening or Non-Screening Indications
Assignment of indication
Indication reported in the ordering provider progress notes before and after serum AFP test was
ordered and performed.
a. Definitely screeninga HCC (or hepatoma or liver cancer) screening or surveillance in patients with no new symptoms, signs, or test
results suggestive of HCC.
b. Definitely non-screening As workup of any symptoms or signs that might be suggestive of HCC including increased (or worsening) liver
function test results; new ascites; weight loss; abdominal pain; abdominal tenderness; abdominal mass;
abdominal distension; abdominal bloating; enlarged liver; palpable liver; failure to thrive; jaundice;
increased bilirubin; variceal bleeding; or fever.
As a follow-up of another positive test result suggestive of HCC: abnormal AFP; liver abnormality on
abdominal ultrasound; liver abnormality on abdominal CT or MRI scan.
Any test done in the emergency room or as an inpatient.
c. Probably screening Screen for HCC and patient also has ascites or encephalopathy (when ascites or encephalopathy are long-
standing or unchanged).b
d. Probably non-screening Rule out HCC, but unclear based on documentation if patient has symptoms or signs suspicious for HCC.
aOnly record as “definitely screening” if there is no simultaneous “non-screening” indication.
bThis refers to serum AFP tests ordered in patients who have ascites or encephalopathy that are long-standing and being
treated, without any obvious concern that development of HCC might have contributed to the ascites or encephalopathy.
Supplemental Table 5.Comparison of Cases and Controls for Occurrence of Screening for HCC With Serum AFP and USS vs Only 1 of the 2 Tests or None
Controls
(n ¼ 238), n (%)
Cases
(n ¼ 238), n (%)
OR (95% CI),
AFP þ USS vs
USS only
Adjusteda OR
(95% CI), AFP þ
USS vs USS only
OR (95% CI),
AFP þ USS vs
AFP only
Adjusteda OR
(95% CI), AFP þ





(95% CI), AFP þ
USS vs neither
0–4 y before index date
None 49 (20.6) 45 (18.9) 1 1
USS only 14 (5.9) 15 (6.3) 1 1
AFP only 60 (25.2) 67 (28.2) 1 1
USS þ AFP 115 (48.3) 111 (46.6) 0.86 (0.29–2.55) 1.35 (0.38–4.82) 0.97 (0.58–1.61) 1.09 (0.63–1.88) 0.90 (0.49–1.68) 0.87 (0.44–1.72)
0–3 y before index date
None 61 (25.6) 56 (23.5) 1 1
USS only 13 (5.5) 14 (5.9) 1 1
AFP only 60 (25.2) 70 (29.4) 1 1
USS þ AFP 104 (43.7) 98 (41.2) 0.86 (0.29–2.55) 1.23 (0.35–4.33) 0.75 (0.44–1.27) 0.84 (0.48–1.48) 1.15 (0.63–2.09) 1.21 (0.63–2.33)
0–2 y before index date
None 78 (32.8) 73 (30.7) 1 1
USS only 15 (6.3) 14 (5.9) 1 1
AFP only 65 (27.3) 74 (31.1) 1 1
USS þ AFP 80 (33.6) 77 (32.4) 1.67 (0.40–6.97) 2.07 (0.44–9.66) 0.63 (0.34–1.16) 0.79 (0.41–1.53) 1.28 (0.69–2.37) 1.33 (0.69–2.57)
0–1 y before index date
None 111 (46.6) 95 (39.9) 1 1
USS only 18 (7.6) 22 (9.2) 1 1
AFP only 65 (27.3) 73 (30.7) 1 1
USS þ AFP 44 (18.5) 48 (20.2) 0.60 (0.14–2.51) 0.65 (0.12–3.62) 0.87 (0.41–1.82) 0.97 (0.44–2.16) 1.67 (0.81–3.41) 1.57 (0.73–3.34)
aAdjusted for age, etiology of cirrhosis, MELD score at cirrhosis diagnosis, race and ethnicity, year of cirrhosis diagnosis, diabetes, alcohol use disorders, body mass index,
receipt of abdominal CT or MRI during the period of interest, and eradication of HCV by antiviral treatment.
Supplemental Table 6.Comparison of Cases and Controls for Occurrence of Definite or Probable Screening Ultrasound,
Screening AFP, or USS or AFP at Given Intervals Before Index Date
Controls (n ¼ 238), n (%) Cases (n ¼ 238), n (%) OR (95% CI) Adjusteda OR (95% CI)
0–4 y before index date
USS 131 (55.0) 128 (53.8) 0.95 (0.66–1.37) 0.94 (0.63–1.41)
AFP 175 (73.5) 178 (74.8) 1.07 (0.70–1.65) 1.09 (0.67–1.76)
USS or AFP 190 (79.8) 193 (81.1) 1.09 (0.68–1.75) 1.07 (0.66–1.75)
0–3 y before index date
USS 119 (50.0) 113 (47.5) 0.90 (0.63–1.30) 0.89 (0.59–1.34)
AFP 165 (69.3) 168 (70.6) 1.07 (0.71–1.59) 1.13 (0.72–1.77)
USS or AFP 178 (74.8) 182 (76.5) 1.10 (0.72–1.69) 1.10 (0.70–1.73)
0–2 y before index date
USS 97 (40.8) 91 (38.2) 0.89 (0.61–1.31) 0.88 (0.57–1.35)
AFP 146 (61.3) 152 (63.9) 1.13 (0.76–1.69) 1.22 (0.78–1.91)
USS or AFP 161 (67.6) 166 (69.7) 1.12 (0.74–1.68) 1.13 (0.73–1.74)
0–1 y before index date
USS 65 (27.3) 70 (29.4) 1.11 (0.74–1.67) 1.08 (0.70–1.68)
AFP 110 (46.2) 122 (51.3) 1.24 (0.85–1.79) 1.25 (0.84–1.86)
USS or AFP 128 (53.8) 144 (60.5) 1.33 (0.92–1.92) 1.40 (0.95–2.07)
aAdjusted for age, etiology of cirrhosis, MELD score at cirrhosis diagnosis, race and ethnicity, year of cirrhosis diagnosis,
diabetes, alcohol use disorders, body mass index, receipt of abdominal CT or MRI during the period of interest, and eradi-
cation of HCV by antiviral treatment. Also, USS analysis was adjusted for serum AFP and serum AFP analysis was adjusted for
USS.
Supplemental Table 7.Comparison of Cases and Controls for Occurrence of Definite or Probable Screening for HCC With Serum AFP and USS vs Only 1 of the 2 Tests or
None
Controls
(n ¼ 238), n (%)
Cases
(n ¼ 238), n (%)
OR (95% CI),
AFP þ USS vs
USS only
Adjusteda OR
(95% CI), AFP þ
USS vs USS only
OR (95% CI),
AFP þ USS vs
AFP only
Adjusteda OR
(95% CI), AFP þ





(95% CI), AFP þ
USS vs none
0–4 y before index date
None 48 (20.2) 45 (18.9) 1 1
USS only 15 (6.3) 15 (6.3) 1 1
AFP only 59 (24.8) 65 (27.3) 1 1
USS þ AFP 116 (48.7) 113 (47.5) 0.86 (0.29–2.55) 1.37 (0.38–4.93) 0.97 (0.58–1.61) 1.06 (0.61–1.83) 0.95 (0.52–1.76) 0.93 (0.48–1.82)
0–3 y before index date
None 60 (25.2) 56 (23.5) 1 1
USS only 13 (5.5) 14 (5.9) 1 1
AFP only 59 (24.8) 69 (29.0) 1 1
USS þ AFP 106 (44.5) 99 (41.6) 0.86 (0.29–2.55) 1.23 (0.35–4.33) 0.75 (0.44–1.27) 0.84 (0.48–1.48) 1.09 (0.61–1.95) 1.12 (0.60–2.08)
0–2 y before index date
None 77 (32.4) 72 (30.3) 1 1
USS only 15 (6.3) 14 (5.9) 1 1
AFP only 64 (26.9) 75 (31.5) 1 1
USS þ AFP 82 (34.5) 77 (32.4) 1.67 (0.40–6.97) 2.07 (0.44–9.66) 0.63 (0.34–1.16) 0.77 (0.40–1.47) 1.15 (0.63–2.09) 1.18 (0.63–2.23)
0–1 y before index date
None 110 (46.2) 94 (39.5) 1 1
USS only 18 (7.6) 22 (9.2) 1 1
AFP only 63 (26.5) 74 (31.1) 1 1
USS þ AFP 47 (19.7) 48 (20.2) 0.60 (0.14–2.51) 0.65 (0.12–3.62) 0.81 (0.39–1.69) 0.88 (0.40–1.93) 1.43 (0.72–2.83) 1.31 (0.64–2.67)
aAdjusted for age, etiology of cirrhosis, MELD score at cirrhosis diagnosis, race and ethnicity, year of cirrhosis diagnosis, diabetes, alcohol use disorders, body mass index,
receipt of abdominal CT or MRI during the period of interest, and eradication of HCV by antiviral treatment.
